NEW YORK (
CHANGE IN RATINGS
upgraded at Collins Stewart from Sell to Hold. Health care segment is showing signs of stabilization.
estimates, target reduced at Goldman. Shares of AET now seen reaching $37. Estimates also lowered, as the company faces multiple headwinds. Neutral rating.
estimates raised at UBS. AET estimates were increased through 2011. Company has multiple earnings tailwinds. Buy rating and $38 price target.
upgraded at Collins Stewart. AMZN was upgraded to Buy. $150 price target. Stock is down 15% from its recent highs, and believe that the Kindle will continue to grow.
downgraded at Keybanc. ARG was downgraded from Buy to Hold. APD will likely have to raise its bid, but the risk/reward is no longer as attractive.
upgraded at Citigroup. AZO was upgraded from Hold to Buy. Company could gain market share and increase operating margins. Also expect to see an aggressive buyback program. New $188 price target.
downgraded at Brean Murray. BMRN was downgraded from Buy to Hold. Valuation call, as the stock is already pricing in good news from Phase 2 products.
rated new Buy at Citigroup. BRCM was initiated with a Buy rating. $35 price target. Company is a classic growth story, with leverage to an improving economic cycle.
price target raised at BofA/Merrill. EMR price target increased to $56 from $50 following upbeat analyst meeting. Organic growth will return to positive territory in 2H10, said Bank of America/Merrill Lynch. 2010 and 2011 EPS estimates lifted to $2.35 and $2.95, respectively. Buy rating.
upgraded at Morgan Stanley from Equal-weight to Overweight. $35 price target. Company is positioned well for a housing recovery.
upgraded at Susquehanna. ICE was upgraded to Positive. $114 price target. Company should see better results from OTC energy trading.
upgraded at Keybanc. IDA was upgraded from Hold to Buy. $33 price target. Recent rate settlement was favorable, and not yet priced into the stock.
downgraded at Credit Suisse to Neutral from Outperform as state budget pressures could weigh on the company's margins and revenue. Price target remains at $20.
rated new Neutral at Goldman. $30 price target. Pending reform is an overhang, despite the company's exposure to growing global credit.
rated new Neutral at Goldman. $35 price target. Company lower relative margins, but strong earnings visibility.
upgraded at Morgan Stanley. NWL was upgraded from Equal-weight to Overweight. $18 price target. Stock is near trough valuation, and has an attractive risk/reward profile.
upgraded at Credit Suisse. PCU upgraded to Outperform from Underperform on higher copper prices. Price target raised to $34 from $31.50. 2009 and 2010 EPS estimates set at $1.09 and $2.13, respectively.
upgraded at FBR. WFSL was upgraded from Market Perform to Outperform. $22 price target. Stock is attractive following a recent pullback, and the company is rich with capital.
upgraded at Collins Stewart from Hold to Buy. $80 price target. Market is underestimating the value of the XTO deal.
STOCK COMMENTS / EPS CHANGES
estimates increased at UBS. BKC estimates were raised through 2011. Company is realizing higher margins, despite weaker sales. Neutral rating and $18 price target.
numbers cut at Goldman. Shares of BSX now seen reaching $9. Estimates were also lowered, because of deteriorating industry pricing. Neutral rating.
target boosted at Morgan Stanley. Shares of EMR now seen reaching $50. Company likely to continue posting sequential order growth. Equal-weight rating.
numbers lowered at FBR. ETFC estimates were reduced through 2011. Company is cutting is commissions, because of price competition. Outperform rating and new $2 price target.
estimates, target raised at UBS. Shares of FMC now seen reaching $67, UBS said. Estimates also boosted, to reflect new momentum in soda ash. Buy rating.
estimates, target cut at Deutsche. Shares of FSLR now seen reaching $125. Estimates also lowered, to reflect difficult industry fundamentals. Hold rating.
cut from Conviction Sell List at Goldman. GENZ was removed from the Conviction Sell list. Regulatory and manufacturing risks are largely behind the company. New $52 price target.
estimates, target raised at Morgan Stanley. ITT estimates were boosted through 2011. Company is seeing strong demand across the board, even though Defense orders are facing tough comps. Equal-weight rating and new $59 price target.
estimates, target boosted at UBS. LEA estimates were increased through 2010. Company likely to see increased operating margins. Buy rating and new $87 price target.
estimates, target reduced at Goldman. Shares of MDT now seen reaching $43. Estimates also lowered, because of poor industry pricing. Neutral rating.
numbers upped at Goldman. Shares of NOC now seen reaching $50. Estimates also raised, because of pension tailwinds. Sell rating.
estimates, target upped at FBR. Shares of NVDA now seen reaching $17. Estimates also raised, as checks suggest that business is running ahead of plan. Market Perform rating.
estimates boosted at Goldman. SLE estimates were raised through 2011. Company is seeing a lower tax rate and is being helped by falling commodity costs.
added to Conviction Sell List at Goldman. STJ was added to the Conviction Sell list. $35 price target. Consensus estimates are likely to head lower, given the company's leverage to the ICD market.
numbers increased at UBS. Shares of TRV now seen reaching $58. Estimates were also raised, to reflect share repurchase activity. Buy rating.
estimates upped at Morgan Stanley. TSN estimates were raised through 2011. Company is realizing higher profit margins in chicken. Equal-weight rating.
estimates cut at Goldman. WY estimates were lowered through 2011. Company is facing higher interest expenses. Neutral rating and $45 price target.
estimates boosted at UBS. YUM estimates were upped through 2011. Seeing better US trends at Pizza Hut and Taco Bell. Neutral rating and $38 price target.
This article was written by a staff member of TheStreet.com.